{"id":{"repo_id":"bu","oai_identifier":"oai:open.bu.edu:2144/49680"},"canonical_url":"https://search.ndltd.org/etd/bu/oai:open.bu.edu:2144/49680","repository":{"repo_id":"bu","name":"Boston University","base_url":"https://open.bu.edu/oai/request"},"display":{"title":"Representation in breast cancer clinical trials","abstract":"Artificial Intelligence (AI) has transformed health care with improved predictions, diagnostics, and treatments by using advanced analytics and models on data. In cancer, especially breast cancer treatment, clinical trials are an essential resource. Yet, very few people from diverse backgrounds have been included in these studies, which can lead to biases against underrepresented groups in health innovations. This thesis explores demo- graphic disparities in breast cancer clinical trials across the United States by analyzing representation patterns and what that means for equity in clinical research. Findings emphasize the need for inclusive trial designs and robust data collection with the aim of guiding equitable and e↵ective treatment development. I also point out that, while achieving equitable representation in clinical trials would be a great improvement, it is still not enough to support machine-learning classifiers used in diagnosis and genetic analysis, which generally require equal numbers of cases in training data for each class.","abstract_html":"Artificial Intelligence (AI) has transformed health care with improved predictions, diagnostics, and treatments by using advanced analytics and models on data. In cancer, especially breast cancer treatment, clinical trials are an essential resource. Yet, very few people from diverse backgrounds have been included in these studies, which can lead to biases against underrepresented groups in health innovations. This thesis explores demo- graphic disparities in breast cancer clinical trials across the United States by analyzing representation patterns and what that means for equity in clinical research. Findings emphasize the need for inclusive trial designs and robust data collection with the aim of guiding equitable and e↵ective treatment development. I also point out that, while achieving equitable representation in clinical trials would be a great improvement, it is still not enough to support machine-learning classifiers used in diagnosis and genetic analysis, which generally require equal numbers of cases in training data for each class.","abstract_has_math":false,"creators":["Alaoeasheg, Maya"],"institution":"Boston University","degree_name":"Master of Science","degree_level":"masters","degree_discipline":"Data Science","degree_department":null,"school":null,"contributors":[],"advisors":["Wildman, Wesley J."],"committee_chairs":[],"committee_members":[],"year":2025,"date_issued":"2025","date_published":"2025","updated_at":"2026-11-18T19:49:29Z","subjects":["Information science","Artificial intelligence","Breast cancer","Clinical trials","Data science","Representation"],"languages":["en_US"],"rights":["Attribution-NonCommercial-ShareAlike 4.0 International"],"rights_urls":["http://creativecommons.org/licenses/by-nc-sa/4.0/"],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":"https://hdl.handle.net/2144/49680","outbound_label":"Handle","outbound_source":"dc:identifier.uri","record_url":"https://hdl.handle.net/2144/49680","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier.uri","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://open.bu.edu/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Aopen.bu.edu%3A2144%2F49680","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Wildman, Wesley J."]},{"key":"dc:creator","label":"Author","values":["Alaoeasheg, Maya"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2025-02-03T18:09:55Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2025-02-03T18:09:55Z"]},{"key":"dc:date.issued","label":"Date","values":["2025"]},{"key":"dc:date.updated","label":"Dc Date Updated","values":["2025-02-03T17:01:39Z"]},{"key":"dc:type","label":"Dc Type","values":["Thesis/Dissertation"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Data Science"]},{"key":"thesis:degree_level","label":"Degree Level","values":["masters"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Master of Science"]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["Boston University"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Information science","Artificial intelligence","Breast cancer","Clinical trials","Data science","Representation"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en_US"]},{"key":"dc:rights","label":"Dc Rights","values":["Attribution-NonCommercial-ShareAlike 4.0 International"]},{"key":"dc:rights.uri","label":"Rights URI","values":["http://creativecommons.org/licenses/by-nc-sa/4.0/"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://hdl.handle.net/2144/49680"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["2025"]},{"key":"dc:description.abstract","label":"Abstract","values":["Artificial Intelligence (AI) has transformed health care with improved predictions, diagnostics, and treatments by using advanced analytics and models on data. In cancer, especially breast cancer treatment, clinical trials are an essential resource. Yet, very few people from diverse backgrounds have been included in these studies, which can lead to biases against underrepresented groups in health innovations. This thesis explores demo- graphic disparities in breast cancer clinical trials across the United States by analyzing representation patterns and what that means for equity in clinical research. Findings emphasize the need for inclusive trial designs and robust data collection with the aim of guiding equitable and e↵ective treatment development. I also point out that, while achieving equitable representation in clinical trials would be a great improvement, it is still not enough to support machine-learning classifiers used in diagnosis and genetic analysis, which generally require equal numbers of cases in training data for each class."]},{"key":"dc:title","label":"Title","values":["Representation in breast cancer clinical trials"]}]}],"canonical_facts":{"dc:contributor.advisor":["Wildman, Wesley J."],"dc:creator":["Alaoeasheg, Maya"],"dc:date.accessioned":["2025-02-03T18:09:55Z"],"dc:date.available":["2025-02-03T18:09:55Z"],"dc:date.issued":["2025"],"dc:date.updated":["2025-02-03T17:01:39Z"],"dc:description":["2025"],"dc:description.abstract":["Artificial Intelligence (AI) has transformed health care with improved predictions, diagnostics, and treatments by using advanced analytics and models on data. In cancer, especially breast cancer treatment, clinical trials are an essential resource. Yet, very few people from diverse backgrounds have been included in these studies, which can lead to biases against underrepresented groups in health innovations. This thesis explores demo- graphic disparities in breast cancer clinical trials across the United States by analyzing representation patterns and what that means for equity in clinical research. Findings emphasize the need for inclusive trial designs and robust data collection with the aim of guiding equitable and e↵ective treatment development. I also point out that, while achieving equitable representation in clinical trials would be a great improvement, it is still not enough to support machine-learning classifiers used in diagnosis and genetic analysis, which generally require equal numbers of cases in training data for each class."],"dc:identifier.uri":["https://hdl.handle.net/2144/49680"],"dc:language.iso":["en_US"],"dc:rights":["Attribution-NonCommercial-ShareAlike 4.0 International"],"dc:rights.uri":["http://creativecommons.org/licenses/by-nc-sa/4.0/"],"dc:subject":["Information science","Artificial intelligence","Breast cancer","Clinical trials","Data science","Representation"],"dc:title":["Representation in breast cancer clinical trials"],"dc:type":["Thesis/Dissertation"],"thesis:degree_discipline":["Data Science"],"thesis:degree_level":["masters"],"thesis:degree_name":["Master of Science"],"thesis:institution_name":["Boston University"]},"updated_at":"2026-11-18T19:49:29Z"}